GenSight Biologics (SIGHT) Q2 2025 TU earnings summary

Executive summary

• Operations funded until early October 2025 due to disciplined spending and recent financing.

• Regulatory progress with ANSM to consider opening the LUMEVOQ AAC program in France in Q4 2025.

• Technology transfer of LUMEVOQ's manufacturing process to Catalent completed, supporting future clinical and regulatory milestones.

Financial highlights

• Cash and cash equivalents at €0.3 million as of June 30, 2025, down from €0.9 million on March 31, 2025.

• Private placement financing of approximately €3.9 million closed in July 2025.

• Additional €0.2 million in Research Tax Credit expected in September 2025.

• EUR 0.7 million from financing used to repay convertible bonds.

Outlook and guidance

• Anticipated AAC program launch in France in October 2025 to provide a cash pathway through H2 2026.

• Phase III RECOVER trial and UK MHRA marketing application for LUMEVOQ planned for H2 2026.

• In Q1 2026, a precise view of residual financing needs will inform further funding strategy.

• Medium-term options include licensing, paid access programs, EIB loan tranche, partnering, or M&A.